DYP688

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DYP688, covering 2025-07-20 to 2025-07-20. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas [Phase 1, Phase 2]

See pricing